AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37632249 — intervention group
Group type: COMPARATOR
Intervention: Single aspiration
Number of subjects: 105
Study 37632341 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition intervention components (up to five components over 3 months)
Number of subjects: 31
Study 37632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6250
Study 37632455 — intervention group
Group type: COMPARATOR
Intervention: Outpatient oral diuretic intensification
Number of subjects: 6250
Study 37632455 — intervention group
Group type: COMPARATOR
Intervention: HF hospitalization
Number of subjects: 6250
Study 37632455 — intervention group
Group type: COMPARATOR
Intervention: Expanded composite end point (cardiovascular death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification)
Number of subjects: 6250
Study 37632452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO + IPI)
Number of subjects: 0
Study 37632452 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab plus axitinib (PEM + AXI)
Number of subjects: 0
Study 37632469 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (PCSK9 inhibitor)
Number of subjects: 11970
Study 37632469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11970
Study 37632463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 3065
Study 37632463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3065
Study 37632466 — intervention group
Group type: EXPERIMENTAL
Intervention: Five modifiable risk factors (body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, diabetes)
Number of subjects: 1518028
Study 37632493 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-LVAD implantation (Visit 1 before implantation)
Number of subjects: 10
Study 37632493 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-LVAD implantation (Visit 2 after implantation with pump speed held constant)
Number of subjects: 10
Study 37632493 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-LVAD implantation (Visit 3 with increased pump speed during exercise)
Number of subjects: 10
Study 37632493 — intervention group
Group type: COMPARATOR
Intervention: Preimplantation testing
Number of subjects: 10
Study 37632515 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential target multiplexed spinal cord stimulation (SCS) with increased stimulation amplitude to a maximum tolerable value
Number of subjects: 24
Study 37632515 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential target multiplexed spinal cord stimulation (SCS)
Number of subjects: 24
Study 37632592 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (10, 15, or 20 mg/m2) in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide)
Number of subjects: 28
Study 37632592 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 28
Study 37632656 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour/day foslevodopa/foscarbidopa CSCI at individually optimized therapeutic doses (approximately 700-4250 mg of LD per 24 hours)
Number of subjects: 244
Study 37632656 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour/day foslevodopa/foscarbidopa CSCI
Number of subjects: 244
Study 37632666 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 biosimilar adalimumab
Number of subjects: 955
Study 37632909 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen (SPF 30)
Number of subjects: 22
Study 37632909 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic sunscreen (SPF 30)
Number of subjects: 22
Study 37632909 — intervention group
Group type: COMPARATOR
Intervention: Comparison of inorganic vs organic sunscreen after swimming
Number of subjects: 22
Study 37632942 — intervention group
Group type: EXPERIMENTAL
Intervention: ASICA intervention (digital health care intervention providing monthly prompts for TSSE and access to a dermatology nurse)
Number of subjects: 22
Study 37632942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study 37632976 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led surveillance (skin self-examination with patient-performed teledermoscopy)
Number of subjects: 100
Study 37632976 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study 37632977 — intervention group
Group type: EXPERIMENTAL
Intervention: eSkinHealth app
Number of subjects: 24
Study 37632977 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 24
Study 37633156 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 mg daily from days 1-21, Itraconazole 100 mg twice daily from days 1-21, Azacitidine 100 mg subcutaneously once daily from days 1-7
Number of subjects: 15
Study 37633159 — intervention group
Group type: EXPERIMENTAL
Intervention: High Definition-tDCS (direct current)
Number of subjects: 0
Study 37633159 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz HD-tACS (alternating current)
Number of subjects: 0
Study 37633255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 53
Study 37633255 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical controls (NS)
Number of subjects: 53
Study 37633275 — intervention group
Group type: EXPERIMENTAL
Intervention: MRG-001
Number of subjects: 21
Study 37633275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate MRG-001 dose
Number of subjects: 21
Study 37633275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 37633306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 543
Study 37633306 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 543
Study 37633331 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified whole wheat flour (BFW)
Number of subjects: 273
Study 37633331 — intervention group
Group type: EXPERIMENTAL
Intervention: Postharvest fortified wheat (PHFW)
Number of subjects: 273
Study 37633331 — intervention group
Group type: COMPARATOR
Intervention: Control wheat (CW)
Number of subjects: 273
Study 37633572 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week internet-delivered CBT intervention
Number of subjects: 85
Study 37633576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs-guided excision
Number of subjects: 87
Study 37633576 — intervention group
Group type: COMPARATOR
Intervention: Traditional excision
Number of subjects: 87
Study 37633589 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG 52 mg IUD
Number of subjects: 39
Study 37633589 — intervention group
Group type: COMPARATOR
Intervention: CuT380 IUD
Number of subjects: 39
Study 37633858 — intervention group
Group type: EXPERIMENTAL
Intervention: Father-reported parenting
Number of subjects: 326
Study 37633858 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-reported parenting
Number of subjects: 326
Study 37633858 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies between father and adolescent perceptions
Number of subjects: 326
Study 37633900 — intervention group
Group type: EXPERIMENTAL
Intervention: LIMK1 hemideletion and haplotype variation
Number of subjects: 33
Study 37633900 — intervention group
Group type: EXPERIMENTAL
Intervention: LIMK1 variation
Number of subjects: 33
Study 37633916 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week VR experience program
Number of subjects: 216
Study 37633916 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by the LTCF
Number of subjects: 216
Study 37633944 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital cardiac arrest (OHCA) survivors
Number of subjects: 108
Study 37634022 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inflammatory demyelinating polyneuropathy (AIDP)
Number of subjects: 62
Study 37634022 — intervention group
Group type: COMPARATOR
Intervention: Acute axonal GBS
Number of subjects: 62
Study 37634058 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR 2011 criteria
Number of subjects: 200
Study 37634058 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR 2016 criteria
Number of subjects: 200
Study 37634058 — intervention group
Group type: EXPERIMENTAL
Intervention: FS scale with cutoff value 11 points
Number of subjects: 200
Study 37634087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6261
Study 37634087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6261
Study 37634089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone supplementation for 7 days prior to the second questionnaire.
Number of subjects: 286
Study 37634089 — intervention group
Group type: COMPARATOR
Intervention: Non-progesterone group (control).
Number of subjects: 286
Study 37634092 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 2008
Study 37634092 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 2008
Study 37634128 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 57
Study 37634135 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation and guideline-directed medical therapy
Number of subjects: 194
Study 37634135 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 194
Study 37634144 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR-guided revascularization
Number of subjects: 4511
Study 37634144 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided revascularization
Number of subjects: 4511
Study 37634145 — intervention group
Group type: EXPERIMENTAL
Intervention: ECLS plus usual medical treatment
Number of subjects: 420
Study 37634145 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual medical treatment alone)
Number of subjects: 420
Study 37634148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation
Number of subjects: 607
Study 37634148 — intervention group
Group type: COMPARATOR
Intervention: Conventional thermal ablation
Number of subjects: 607
Study 37634149 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 1201
Study 37634149 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1201
Study 37634150 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 1445
Study 37634150 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only revascularization
Number of subjects: 1445
Study 37634187 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-guided TAVR
Number of subjects: 380
Study 37634187 — intervention group
Group type: COMPARATOR
Intervention: CT-guided TAVR
Number of subjects: 380
Study 37634188 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 2487
Study 37634188 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 2487
Study 37634190 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate multivessel PCI
Number of subjects: 840
Study 37634190 — intervention group
Group type: COMPARATOR
Intervention: Staged multivessel PCI
Number of subjects: 840
Study 37634234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (DXM20)
Number of subjects: 473
Study 37634234 — intervention group
Group type: COMPARATOR
Intervention: Standard of care 6 mg dose of dexamethasone (DXMSoC)
Number of subjects: 473
Study 37634517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate isoniazid preventive therapy (28 weeks isoniazid [300 mg daily], then placebo until week 40 after delivery)
Number of subjects: 749
Study 37634517 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (placebo until week 12 after delivery, then isoniazid [300 mg daily] for 28 weeks)
Number of subjects: 749
Study 37634517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate isoniazid preventive therapy
Number of subjects: 749
Study 37634517 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 749
Study 37634520 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive CRT (synchronised left ventricular stimulation)
Number of subjects: 3617
Study 37634520 — intervention group
Group type: COMPARATOR
Intervention: Conventional CRT (biventricular CRT)
Number of subjects: 3617
Study 37634629 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 inhibitor in combination with standard systemic treatment
Number of subjects: 15
Study 37634655 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-factor Xa NOAC (apixaban 5 mg twice per day, edoxaban 60 mg daily, or rivaroxaban 20 mg daily for 12 months)
Number of subjects: 360
Study 37634655 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction and stroke), and death from any cause at 12 months
Number of subjects: 360
Study 37634655 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 75 mg daily indefinitely (control group)
Number of subjects: 360
Study 37634707 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing SGLT2 inhibitors in patients with HF and eGFR <25 mL/min/1.73 m²
Number of subjects: 11007
Study 37634859 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP-ADC < 33%
Number of subjects: 273
Study 37634859 — intervention group
Group type: COMPARATOR
Intervention: ABP-ADC group (30-35%)
Number of subjects: 273
Study 37634859 — intervention group
Group type: COMPARATOR
Intervention: ABP-ADC group (>35%)
Number of subjects: 273
Study 37634859 — intervention group
Group type: COMPARATOR
Intervention: ABP-ADC group (<30%)
Number of subjects: 273
Study 37635157 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 37635160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic warm-up intervention (DWU)
Number of subjects: 92
Study 37635160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid warm-up intervention (HWU)
Number of subjects: 92
Study 37635160 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching warm-up intervention (SWU)
Number of subjects: 92
Study 37635160 — intervention group
Group type: COMPARATOR
Intervention: No warm-up intervention (CONTROL)
Number of subjects: 92
Study 37635200 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Group (EG) - endoscopic untwist of sigmoid colon followed by endoscopic fixation under sedation
Number of subjects: 18
Study 37635200 — intervention group
Group type: COMPARATOR
Intervention: Surgical Group (SG) - surgical fixation of sigmoid colon or sigmoidectomy after initial simple loop colostomy under general anesthesia
Number of subjects: 18
Study 37635200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 37635707 — intervention group
Group type: EXPERIMENTAL
Intervention: BASET score
Number of subjects: 144
Study 37635707 — intervention group
Group type: COMPARATOR
Intervention: STOP-Bang score
Number of subjects: 144
Study 37635707 — intervention group
Group type: COMPARATOR
Intervention: Berlin score
Number of subjects: 144
Study 37635769 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time only subcutaneous apomorphine infusion
Number of subjects: 42
Study 37635784 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic flow parameters derived from 2D phase-contrast cardiovascular magnetic resonance imaging
Number of subjects: 169
Study 37635813 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCN resectability status classification
Number of subjects: 69
Study 37635813 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of vascular invasion
Number of subjects: 69
Study 37635815 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction systemic therapy with doublet or triplet chemotherapy plus targeted therapy
Number of subjects: 173
Study 37635843 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized training with Web-based cognitive games
Number of subjects: 107
Study 37635843 — intervention group
Group type: COMPARATOR
Intervention: Web-based crossword puzzles
Number of subjects: 107
Study 37635913 — intervention group
Group type: EXPERIMENTAL
Intervention: One motivational interviewing session plus up to four weeks of patient navigation
Number of subjects: 440
Study 37635913 — intervention group
Group type: COMPARATOR
Intervention: One motivational interviewing session
Number of subjects: 440
Study 37635913 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 440
Study 37636251 — intervention group
Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5%
Number of subjects: 535
Study 37636253 — intervention group
Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5%
Number of subjects: 733
Study 37636253 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 733
Study 37636296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and/or postconditioning treatment in addition to conventional percutaneous coronary intervention
Number of subjects: 566
Study 37636296 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous coronary intervention
Number of subjects: 566
Study 37637060 — intervention group
Group type: EXPERIMENTAL
Intervention: Supradiaphragmatic lymphadenectomy during primary debulking surgery (PDS)
Number of subjects: 120
Study 37637060 — intervention group
Group type: COMPARATOR
Intervention: Interval debulking surgery after neoadjuvant chemotherapy (IDS/NAC)
Number of subjects: 120
Study 37637060 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual tumors in the abdominal area measuring ≥5 mm
Number of subjects: 120
Study 37637187 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA + PPI
Number of subjects: 66
Study 37637187 — intervention group
Group type: COMPARATOR
Intervention: PPI
Number of subjects: 66
Study 37637218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 0
Study 37637218 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 37637234 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of autoimmune allele
Number of subjects: 55
Study 37637440 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation (HL)
Number of subjects: 196
Study 37637440 — intervention group
Group type: COMPARATOR
Intervention: Low ligation (LL)
Number of subjects: 196
Study 37637501 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE-iNKT (Transarterial Embolization with biweekly iNKT cell infusion)
Number of subjects: 60
Study 37637501 — intervention group
Group type: COMPARATOR
Intervention: TAE (Transarterial Embolization without iNKT cell infusion)
Number of subjects: 60
Study 37637501 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE-iNKT
Number of subjects: 60
Study 37637850 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous afferent patterned stimulation (TAPS) therapy, unsupervised at-home sessions twice daily for four weeks
Number of subjects: 40
Study 37637850 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous afferent patterned stimulation (TAPS) therapy
Number of subjects: 40
Study 37637880 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Tumor Volume (TTV) response assessment
Number of subjects: 210
Study 37637880 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV decrease of more than 10%
Number of subjects: 210
Study 37637880 — intervention group
Group type: COMPARATOR
Intervention: RECIST1.1
Number of subjects: 210
Study 37637902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 36
Study 37637902 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 36
Study 37637935 — intervention group
Group type: EXPERIMENTAL
Intervention: M8891 (7-80 mg once daily in 21-day cycles)
Number of subjects: 27
Study 37638077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane 3 ml
Number of subjects: 15
Study 37638077 — intervention group
Group type: COMPARATOR
Intervention: i.v. fentanyl 25 μg
Number of subjects: 15
Study 37638077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 37638079 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsQoR-10-French questionnaire at H24 after delivery
Number of subjects: 500
Study 37638079 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsQoR-10-French questionnaire at H48 after delivery
Number of subjects: 500
Study 37638079 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsQoR-10-French questionnaire before delivery
Number of subjects: 500
Study 37638083 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg)
Number of subjects: 0
Study 37638083 — intervention group
Group type: COMPARATOR
Intervention: Morphine (control group)
Number of subjects: 0
Study 37638086 — intervention group
Group type: EXPERIMENTAL
Intervention: TI.VA algorithm for anaesthesia management
Number of subjects: 9
Study 37638086 — intervention group
Group type: COMPARATOR
Intervention: Manual control using propofol and remifentanil
Number of subjects: 9
Study 37638196 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT)
Number of subjects: 3000
Study 37638400 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once-daily
Number of subjects: 744
Study 37638409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthermal Point-by-Point Pulmonary Vein Isolation using a Novel Pulsed Field Ablation System
Number of subjects: 0
Study 37638435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT) 24 cGy/6 fractions
Number of subjects: 60
Study 37638435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT) 300 cGy/6 fractions
Number of subjects: 60
Study 37638435 — intervention group
Group type: COMPARATOR
Intervention: Sham radiation therapy (0 cGy/6 fractions)
Number of subjects: 60
Study 37638695 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin (30 mg to 800 mg daily for 14 days)
Number of subjects: 114
Study 37638695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 37638695 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin (single ascending dose of 1 mg to 800 mg)
Number of subjects: 114
Study 37638695 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin (multiple ascending dose)
Number of subjects: 114
Study 37638695 — intervention group
Group type: EXPERIMENTAL
Intervention: Muvalaplin
Number of subjects: 114
Study 37638789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0